BioSpace News Archive

Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, announced its corporate highlights and unaudited financial results for the first half-year of 2020.

Michael Freeman, CEO/CTO of Ocutrx Vision Technologies, LLC, a California-based technology company developing state-of-the-art augmented reality headset devices, will be delivering a highly anticipated keynote speech that will discuss the Surgery Suite of the Future, including the application of Augmented/Extended Reality, “glasses-free” 3D monitors, 5G Edge Computing for hospitals, and Artificial Intelligence.

Oncolytics Biotech® Inc. announced the first patient has been dosed in the Company’s investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer.

CPT Scott Kelly, former NASA astronaut, joins industry experts for inspiring, first-of-its-kind event

Can-Fite BioPharma Ltd. today announced that it will be presenting at the 12th annual LD 500 on Tuesday, September 1, 2020 at 9:20 AM EST / 6:20 AM PST.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Karin Ann Thacker, M.Sc., as Vice President, Regulatory Affairs and Quality Assurance. Ms. Thacker joins Harpoon from Gritstone Oncology where she most recently served as Vice President, Global Regulatory Affairs. “I am pleased to welcome Karin Thacker to Harpoon’s exe

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2020. Key highlights include: Second quarter (Q2) 2020 Net Revenues of $4,771,255 decreased by 7% versus Q2 2019 First half (H1) 2020 Net Revenues of $10,834,101 increased by 12% versus H1 2019 Q2 2020 Canadian Pharmaceutical Net Revenues of $4,415,900 decreased by 9% versus Q2 2019 H1 2020 Canadi

Wireless patient monitoring devices are wireless and remote technologies that monitor and transmit data either within an institution or hospital via wireless or intranet, or at a remote location, using wireless transmissions.

According to the report, the global rare neurodegenerative disease treatment market was valued at US$ 67 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030.

According to the report, the global video telemedicine market was valued at ~US$ 1 Bn in 2019 and is projected to expand at a CAGR of ~13% from 2020 to 2030. Video telemedicine is not a distant possibility in emerging economies.